Certolizumab
- Generic Name
- Certolizumab
- Brand Names
- -
- Drug Type
- -
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Indication
本品与甲氨蝶呤（MTX）合用，用于治疗对改善病情的抗风湿药（DMARDs）（包括MTX）疗效不佳的中重度活动性类风湿关节炎（RA）成年患者。
- Associated Conditions
- -
- Associated Therapies
- -
A Study to Evaluate the Nipocalimab and Certolizumab Combination Therapy in Participants With Active Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2023-09-08
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 103
- Registration Number
- NCT06028438
- Locations
- 🇵🇱
NZOZ Lecznica MAK MED S C, Nadarzyn, Poland
🇭🇺Vital Medical Center Orvosi es Fogaszati Kozpont, Veszprem, Hungary
🇭🇺Budai Irgalmasrendi Korhaz, Budapest, Hungary
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2021-08-05
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT04991025
- Locations
- 🇺🇸
Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities, Basking Ridge, New Jersey, United States
🇺🇸Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey, United States
CHronic Nonbacterial Osteomyelitis International Registry
- First Posted Date
- 2021-01-26
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 2000
- Registration Number
- NCT04725422
- Locations
- 🇺🇸
Seattle Children's Hospital, Seattle, Washington, United States
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Lipids, Inflammation, and CV Risk in RA
- Conditions
- Interventions
- First Posted Date
- 2016-03-22
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Brigham and Women's Hospital
- Target Recruit Count
- 76
- Registration Number
- NCT02714881
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
- First Posted Date
- 2014-05-07
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Jagiellonian University
- Target Recruit Count
- 100
- Registration Number
- NCT02132234
- Locations
- 🇵🇱
Katedra Chorób Wewnętrznych i Medycyny Wsi, Uniwersytet Jagielloński, Krakow, Skarbowa 4, Poland
Certolizumab in Combination With Chemotherapy for Patients With Stage IV Lung Adenocarcinomas
- Conditions
- Interventions
- First Posted Date
- 2014-04-23
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT02120807
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Cancer Center at Phelps Memorial Hospital Center, Sleepy Hollow, New York, United States
EUS Evaluation of Perianal and Peri-rectal Fistulizing Crohn's Disease With CERTOLIZUMAB Treatment
- First Posted Date
- 2012-04-20
- Last Posted Date
- 2016-02-19
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 1
- Registration Number
- NCT01582568
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)
- Conditions
- First Posted Date
- 2010-04-02
- Last Posted Date
- 2015-09-21
- Lead Sponsor
- University of Rochester
- Target Recruit Count
- 5
- Registration Number
- NCT01098201
- Locations
- 🇺🇸
University of Rochester, Rochester, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.